Dataset from A Phase II, Randomised, Double-Blind, Placebo Controlled, Parallel-Group, Multicentre, Three Month Duration Potassium Reduction Initiative to Optimize RAAS Inhibition Therapy With Sodium Zirconium Cyclosilicate in Heart Failure
收藏NIAID Data Ecosystem2026-05-02 收录
下载链接：
https://handle.stage.datacite.org/10.70118/PR00007481
下载链接
链接失效反馈官方服务：
资源简介：
This is an international, multicentre, parallel-group, randomised, double-blind, placebo
controlled, phase II study to evaluate the benefits and risks of using sodium zirconium
cyclosilicate (ZS) to initiate and intensify renin angiotensin aldosterone system inhibitor
(RAASi) therapy in heart failure patients.
创建时间：
2024-11-26
